- Oops!Something went wrong.Please try again later.
Becton, Dickinson and Company BDX, popularly known as BD, is well poised for growth in the coming quarters, backed by its slew of product launches over the past few months. A robust third-quarter fiscal 2021 performance, along with a number of regulatory approvals, is expected to contribute further. Significant consolidation and foreign exchange woes persist.
Over the past year, this Zacks Rank #3 (Hold) stock has gained 11.5% compared with 33.2% growth of the industry and 35.4% rise of the S&P 500.
The renowned medical technology company has a market capitalization of $72.21 billion. The company projects 8.3% growth for the next five years and expects to maintain its strong performance. BD has delivered an earnings surprise of 18.20% for the past four quarters, on average.
Image Source: Zacks Investment Research
Let’s delve deeper.
Regulatory Approvals: We are optimistic about BD’s impressive progress on the regulatory front with respect to its products. The company, in August, announced receipt of the FDA’s Emergency Use Authorization for the BD Veritor At-Home COVID-19 Test. The test is an over-the-counter rapid antigen test that utilizes Scanwell Health mobile app to deliver reliable results in 15 minutes.
BD, in June, announced receipt of the FDA’s 510(k) clearance for its PeritX Peritoneal Catheter System. The system is to be used for the drainage of symptomatic, recurrent non-malignant ascites. In May, the company announced that the industry's first self-collection claim for human papillomavirus (“HPV”) screening has received the CE mark.
Product Launches: We are upbeat about BD’s introduction of a slew of products over the past few months. The company, in August, launched BD COR System, a new and fully automated high-throughput diagnostic system that uses robotics and sample management software algorithms. This is expected to make the BD Onclarity HPV Assay with extended genotyping for the BD COR System available to high-throughput labs that process the majority of cervical cancer screening specimens in the United States.
The same month, BD announced the launch of a new benchtop cell analyzer, BD FACSymphony A1 Cell Analyzer. The fluorescence-activated cell analyzer is expected to equip laboratories of all sizes with sophisticated flow cytometry capabilities.
Strong Q3 Results: BD’s solid third-quarter fiscal 2021 results buoy our optimism. The company recorded robust segmental performances, along with solid geographical revenues, which are impressive. BD’s slew of strategic deals also augurs well. Expansion of both margins bodes well for the stock. A raised financial outlook despite pandemic-led uncertainties is encouraging.
Forex Woes: BD generates a substantial portion of its revenues from international operations. It anticipates that a significant portion of its sales will continue to come from outside the United States in the future. The revenues BD reports with respect to its operations outside the United States may be adversely affected by fluctuations in foreign currency exchange rates. Any hedging activity that the company engages in may only offset a portion of the adverse financial impact resulting from unfavorable changes in foreign currency exchange rates. BD cannot predict with any certainty the changes in foreign currency exchange rates or the degree to which it can mitigate these risks.
Significant Consolidation: The medical technology industry has also experienced a significant amount of consolidation, resulting in companies with greater scale and market presence than BD. Traditional distributors are also manufacturers of medical devices, providing another source of competition. In addition, health care systems and other providers are consolidating, resulting in greater purchasing power for these companies. As a result, competition among medical device suppliers to provide goods and services has increased.
BD is witnessing a positive estimate revision trend for 2021. In the past 90 days, the Zacks Consensus Estimate for its earnings has moved 0.7% north to $12.90.
The Zacks Consensus Estimate for the company’s fourth-quarter fiscal 2021 revenues is pegged at $4.90 billion, suggesting a 2.3% improvement from the year-ago quarter’s reported number.
Some better-ranked stocks from the broader medical space are Henry Schein, Inc. HSIC, IDEXX Laboratories, Inc. IDXX and West Pharmaceutical Services, Inc. WST.
Henry Schein’s long-term earnings growth rate is estimated at 13.9%. The company presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
IDEXX’s long-term earnings growth rate is estimated at 19.9%. It currently has a Zacks Rank #2.
West Pharmaceutical’s long-term earnings growth rate is estimated at 27.3%. It currently carries a Zacks Rank #2.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Becton, Dickinson and Company (BDX) : Free Stock Analysis Report
Henry Schein, Inc. (HSIC) : Free Stock Analysis Report
IDEXX Laboratories, Inc. (IDXX) : Free Stock Analysis Report
West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research